Pulike Biological Engineering (SHG:603566) — Market Cap & Net Worth
Market Cap & Net Worth: Pulike Biological Engineering (603566)
Pulike Biological Engineering (SHG:603566) has a market capitalization of $500.83 Million (CN¥3.42 Billion) as of June 22, 2026. Listed on the SHG stock exchange, this China-based company holds position #12365 globally and #3632 in its home market, demonstrating a -5.54% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pulike Biological Engineering's stock price CN¥9.89 by its total outstanding shares 346062273 (346.06 Million). Review how much debt does Pulike Biological Engineering carry to assess the company's total debt and financial obligations.
Pulike Biological Engineering Market Cap History: 2015 to 2026
Pulike Biological Engineering's market capitalization history from 2015 to 2026. Data shows change from $1.31 Billion to $500.83 Million (-5.54% CAGR).
Pulike Biological Engineering Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pulike Biological Engineering's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.62x
Pulike Biological Engineering's market cap is 0.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.96x
Pulike Biological Engineering's market cap is 6.96 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.31 Billion | $478.14 Million | $141.74 Million | 2.73x | 9.21x |
| 2016 | $1.12 Billion | $583.10 Million | $188.00 Million | 1.91x | 5.94x |
| 2017 | $1.03 Billion | $529.90 Million | $114.19 Million | 1.95x | 9.05x |
| 2018 | $555.27 Million | $608.06 Million | $135.61 Million | 0.91x | 4.09x |
| 2019 | $910.79 Million | $663.19 Million | $109.25 Million | 1.37x | 8.34x |
| 2020 | $1.01 Billion | $928.51 Million | $216.66 Million | 1.08x | 4.64x |
| 2021 | $1.09 Billion | $1.10 Billion | $244.14 Million | 1.00x | 4.48x |
| 2022 | $1.37 Billion | $1.23 Billion | $167.82 Million | 1.11x | 8.14x |
| 2023 | $1.15 Billion | $1.25 Billion | $174.52 Million | 0.92x | 6.57x |
| 2024 | $646.16 Million | $1.04 Billion | $92.81 Million | 0.62x | 6.96x |
Competitor Companies of 603566 by Market Capitalization
Companies near Pulike Biological Engineering in the global market cap rankings as of June 22, 2026.
Key companies related to Pulike Biological Engineering by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Pulike Biological Engineering Historical Marketcap From 2015 to 2026
Between 2015 and today, Pulike Biological Engineering's market cap moved from $1.31 Billion to $ 500.83 Million, with a yearly change of -5.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥500.83 Million | -20.43% |
| 2025 | CN¥629.45 Million | -2.59% |
| 2024 | CN¥646.16 Million | -43.66% |
| 2023 | CN¥1.15 Billion | -16.01% |
| 2022 | CN¥1.37 Billion | +24.76% |
| 2021 | CN¥1.09 Billion | +8.90% |
| 2020 | CN¥1.01 Billion | +10.36% |
| 2019 | CN¥910.79 Million | +64.03% |
| 2018 | CN¥555.27 Million | -46.26% |
| 2017 | CN¥1.03 Billion | -7.45% |
| 2016 | CN¥1.12 Billion | -14.45% |
| 2015 | CN¥1.31 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Pulike Biological Engineering was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $500.83 Million USD |
| MoneyControl | $500.83 Million USD |
| MarketWatch | $500.83 Million USD |
| marketcap.company | $500.83 Million USD |
| Reuters | $500.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pulike Biological Engineering
Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China.